rs2851301 — ADH5 ADH5 Second NF-kB Site Variant

ADH5 Promoter Variant — When Less GSNOR Means Better Breathing

Two adjacent promoter variants in the ADH5 gene sit within a potential NF-κB binding site¹¹ NF-κB binding site
NF-κB (nuclear factor kappa B) is a transcription factor that drives inflammatory gene expression; it binds to specific DNA sequences (kappa B elements) in gene promoters to switch on transcription. rs2851301 is one of these two sites. The hypothesis is that the minor T allele disrupts this binding site — preventing NF-κB from switching on GSNOR transcription during inflammatory episodes — and that this leads to higher levels of the airway bronchodilator S-nitrosoglutathione (GSNO), reducing the risk of asthma.

The Mechanism

ADH5 encodes GSNOR (S-nitrosoglutathione reductase), the enzyme responsible for degrading GSNO in airway lining fluid. GSNO is the primary endogenous bronchodilator in the lungs: it relaxes bronchial smooth muscle at nanomolar concentrations, roughly 100 times more potently than theophylline. In asthmatic airways, total S-nitrosothiol levels are approximately halved²² total S-nitrosothiol levels are approximately halved
Que et al. 2009 measured SNO levels of 11.2 pmol/ml in mild asthmatics vs 23.1 pmol/ml in healthy controls (p=0.01); GSNOR activity was correspondingly elevated at 1,223 vs 537 AU/mg protein (p=0.03).

The NF-κB inflammatory pathway normally upregulates GSNOR during airway inflammation — a paradoxical response that removes the very bronchodilator needed to resolve smooth muscle spasm. rs2851301 and the adjacent rs2602899 lie within a predicted NF-κB response element in the ADH5 promoter. The proposed model: the minor T allele at rs2851301 (or the corresponding allele at rs2602899) disrupts the NF-κB consensus sequence, blunting the inflammation-driven spike in GSNOR transcription. This keeps GSNO levels higher during inflammatory challenge, maintaining bronchodilator reserve precisely when it is most needed.

GSNOR also detoxifies formaldehyde via the glutathione adduct S-hydroxymethylglutathione. Environmental formaldehyde load (from pressed-wood furniture, carpets, cigarette smoke) competes for GSNOR enzyme capacity; T-allele carriers who have lower baseline GSNOR expression may have modestly less formaldehyde clearance capacity, though this has not been directly studied.

The Evidence

rs2851301 was not directly genotyped in the primary association study. Wu et al. 2007³³ Wu et al. 2007
532 nuclear families with asthmatic children aged 4–17 years in Mexico City; family-based association testing using case-parent triads genotyped seven tagging SNPs across the ADH5 locus. The significant protective signal came from rs1154404 (intron 1), where each copy of the minor allele reduced childhood asthma risk (RR 0.77 for one copy, 95% CI 0.61–0.97, P = 0.028; RR 0.66 for two copies, 95% CI 0.44–0.99, P = 0.046). The authors noted that rs1154404 is in near-complete LD (r² = 0.99) with two adjacent promoter SNPs — rs2602899 and rs2851301 — at the NF-κB site, proposing these as the functional variants responsible for the protective signal.

rs2851301 is therefore an inferred protective variant: it tracks the rs1154404 signal almost perfectly, and the biological logic of an NF-κB site disruption at the GSNOR promoter is well-supported by the functional data showing that GSNOR activity correlates with airway hyperresponsiveness. However, because the two promoter variants sit adjacent to each other (complicating direct genotyping) and were not independently associated in a study powered for that purpose, the evidence level for rs2851301 specifically remains emerging.

A 2017 review Barnett & Buxton⁴⁴ Barnett & Buxton
Critical Reviews in Biochemistry and Molecular Biology, vol 52: 340–354; comprehensively reviews GSNOR biology and disease associations reinforces the therapeutic rationale by noting that GSNOR inhibitors (N6022, N91115) have entered clinical trials for asthma and cystic fibrosis, confirming that the enzyme is a validated drug target whose activity level is causally relevant to airway disease.

Practical Actions

For CC carriers (common genotype, ~37% of people), the NF-κB site is intact and GSNOR may respond normally to inflammatory upregulation. Minimising triggers that further stress the GSNOR-GSNO axis — particularly indoor formaldehyde from pressed-wood furniture — is a genotype-specific precaution for those with asthma or atopic history.

For TT carriers (~15% globally), the proposed disruption of the NF-κB site may blunt inflammatory GSNOR upregulation, helping maintain GSNO levels during asthma exacerbations. This protective effect is most relevant in childhood and may attenuate with age. Nitrate-rich vegetables support the inorganic nitrate–nitrite–NO pathway as an independent source of airway bronchodilation.

Interactions

rs2851301 and rs2602899 are two adjacent SNPs at the same NF-κB element; they travel together (r² ≈ 1) and their combined allele state defines the protective haplotype. rs1154404 (intron 1) tags this haplotype with near-perfect precision and is the most studied marker for the protective signal. The high-risk end of the ADH5 allele spectrum is anchored by rs28730619, which tags a haplotype associated with elevated GSNOR activity and 60% increased childhood asthma risk — the mirror image of the rs2851301 protective signal.

The ADRB2 Arg16Gly variant (rs1042713) interacts with GSNOR haplotypes in predicting bronchodilator response to albuterol in Hispanic asthmatic children. For individuals carrying risk variants at both loci, standard short-acting beta-agonist therapy may be less effective.